Announcements
- EQS-News: Sartorius to advance drug discovery and manufacturing with AI in collaboration with NVIDIA
- EQS-News: Sartorius collaborates with Sanofi to commercialize end-to-end platform for downstream process intensification
- EQS-AFR: Sartorius AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements
- EQS-News: Sartorius: First quarter results in line with expectations; recurring business with significant order growth; demand from China remains weak; outlook for full year confirmed
- EQS-DD: Sartorius AG: Dr. Florian Funck, Transfer of 1207 preference shares as a share-based remuneration component in fulfillment of a grant made before the start of the Management Board mandate.
- EQS-DD: Sartorius AG: Dr. Florian Funck, Transfer of 1500 ordinary shares as a share-based remuneration component in fulfillment of a grant made before the start of the Management Board mandate.
- EQS-News: Resolutions of the Annual General Meeting of Sartorius AG
More ▼
Key statistics
As of last trade Sartorius AG (SRT3N:MEX) traded at 5,276.34, -43.85% above its 52-week low of 9,396.15, set on Feb 14, 2022.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 4,876.03 |
Average volume | 0.00 |
---|---|
Shares outstanding | 74.88m |
Free float | 32.69m |
P/E (TTM) | 96.36 |
Market cap | 17.75bn EUR |
EPS (TTM) | 2.18 EUR |
Annual div (ADY) | 13.19 MXN |
---|---|
Annual div yield (ADY) | 0.27% |
Div ex-date | Apr 02 2024 |
Div pay-date | Apr 04 2024 |
Data delayed at least 20 minutes, as of Feb 14 2022 11:30 GMT.
More ▼